Cookie Consent
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
The UK clinical trial system is evolving — from fragmentation to coordinated delivery
The UK clinical research landscape is undergoing a structural shift. What was once characterised by variability in site performance, fragmented feasibility processes and long set-up timelines is increasingly moving towards a more coordinated and standardised delivery model.
This was clearly reflected at the ICR Global Conference in Birmingham.
Across discussions with regulators, NHS stakeholders and industry representatives, a consistent direction emerged: the UK is not only optimising individual parts of the system — it is aligning the system itself.
Regulatory performance is improving — but it is not the main shift
Recent updates shared during the conference indicated that the Medicines and Healthcare products Regulatory Agency is currently operating ahead of its target timelines, with start-up to first patient recruitment averaging around 122 days against a 150-day benchmark.
While this reflects increased regulatory efficiency, it is not the primary driver of change. The more relevant shift is structural.
From site-level execution to system-level delivery
A key development is the closer collaboration between the National Health Service and the National Institute for Health and Care Research through the development of Commercial Research Delivery Centres.
The intention is not to optimise individual sites in isolation, but to build a more consistent delivery infrastructure across the UK.
This includes:
Digitalisation and operational alignment are accelerating across sites
Alongside structural changes, operational transformation is becoming more visible across sites. Electronic investigator site files (eISF) are increasingly being adopted, improving documentation flow and inspection readiness. Feasibility and site selection processes are also being streamlined, supported by more structured collaboration between stakeholders.
These are not isolated improvements — they are part of a broader movement towards operational alignment.
Patient engagement is becoming a structural priority
Another consistent theme across discussions was the role of participant engagement. Rather than being positioned as a supporting activity, engagement is increasingly treated as a core component of study success — influencing feasibility, recruitment performance and overall trial sustainability.
AI as an enabler, not a disruption
Artificial intelligence was discussed in the context of regulatory and operational workflows. The emphasis was not on replacement, but on enablement — particularly in areas such as risk assessment, data handling and decision support within regulatory processes. The underlying view across stakeholders was consistent: AI will enhance efficiency, but human oversight remains central.
What this means for sponsors and CROs
Across all discussions, one question repeatedly surfaced: How can trial delivery be accelerated without compromising quality?
There is no single lever that solves this challenge.
Instead, what is emerging is a coordinated system-level approach — where regulators, sites and infrastructure work more closely aligned than before.
For sponsors and CROs, this shift is not operational detail.
It directly impacts:
A system in transition — not yet optimised, but clearly moving
The UK is not yet a fully optimised clinical trial environment. But it is clearly transitioning towards one.
And for organisations operating in clinical research, the most important change is not speed alone — it is predictability through alignment.
